

Yale Liver Center Research Seminar

*Presented by Yale School of Medicine,
Department of Internal Medicine*

Leveraging Energy Expenditure in the Management of Non-Alcoholic Fatty Liver

David E. Cohen, MD, PhD

Chief, Division of Gastroenterology, Hepatology & Endoscopy
Brigham and Women's Hospital
Harvard Medical School

Tuesday, March 1, 2022 | 5:00-6:00PM

<https://zoom.us/j/94434404595?pwd=UHdpQjl2aXFreENzZVkrSzVxV2RoUT09&from=addon>

Meeting ID: 944 3440 4595

Passcode: 994594

Host: Michael H. Nathanson, MD, PhD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29437) to 203-442-9435.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** NAFLD is the most common chronic liver disease. There are no currently approved therapies, and weight loss remains difficult to achieve in clinical practice. Therefore, there is a need for research that explores new metabolic pathways that may provide targets for intervention. One such approach is to target cellular and biochemical mechanisms of energy conservation. These are essential for survival of the organism under challenging environmental conditions of nutrient deprivation. However, such mechanisms become maladaptive in the setting of overnutrition. **Objectives:** 1. Appreciate that positive energy balance contributes to NAFLD pathogenesis 2. Understand that genetic and biochemical mechanisms contribute to caloric conservation. 3. Appreciate how efforts to target energy balance may prove beneficial in the medical management of NAFLD. **Faculty Disclosures:** Michael H. Nathanson, faculty/planner for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose. David E. Cohen, faculty/planner for this educational event, is an advisor for Novartis and Arrow Diagnostics, and is a board member and/or committee member for Aegerion, PTC Therapeutics, and Esperion. All of the relevant financial relationships listed for these individuals have been mitigated. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**